Enliven Therapeutics Inc (NASDAQ: ELVN)’s stock price has dropped by -11.50 in relation to previous closing price of 23.82. Nevertheless, the company has seen a gain of 8.66% in its stock price over the last five trading days. Proactive Investors reported 2024-04-11 that Enliven Therapeutics spiked to a 52-week high after the precision oncology firm unveiled positive proof of concept data from an early-stage trial of its blood cancer therapeutic. The company released data from its Phase 1 clinical trial evaluating its drug candidate ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs).
Is It Worth Investing in Enliven Therapeutics Inc (NASDAQ: ELVN) Right Now?
Moreover, the 36-month beta value for ELVN is 0.98. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ELVN is 21.40M and currently, short sellers hold a 19.78% of that float. On April 15, 2024, ELVN’s average trading volume was 209.51K shares.
ELVN’s Market Performance
ELVN stock saw an increase of 8.66% in the past week, with a monthly gain of 71.80% and a quarterly increase of 83.78%. The volatility ratio for the week is 14.60%, and the volatility levels for the last 30 days are 11.71% for Enliven Therapeutics Inc (ELVN). The simple moving average for the past 20 days is 18.27% for ELVN’s stock, with a 39.53% simple moving average for the past 200 days.
Analysts’ Opinion of ELVN
Many brokerage firms have already submitted their reports for ELVN stocks, with Mizuho repeating the rating for ELVN by listing it as a “Buy.” The predicted price for ELVN in the upcoming period, according to Mizuho is $34 based on the research report published on April 09, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ELVN reach a price target of $27. The rating they have provided for ELVN stocks is “Buy” according to the report published on March 29th, 2023.
ELVN Trading at 26.87% from the 50-Day Moving Average
After a stumble in the market that brought ELVN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.92% of loss for the given period.
Volatility was left at 11.71%, however, over the last 30 days, the volatility rate increased by 14.60%, as shares surge +82.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.27% upper at present.
During the last 5 trading sessions, ELVN rose by +8.66%, which changed the moving average for the period of 200-days by +9.85% in comparison to the 20-day moving average, which settled at $18.30. In addition, Enliven Therapeutics Inc saw 52.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ELVN starting from Ballal Rahul D., who sale 53,400 shares at the price of $23.95 back on Apr 11 ’24. After this action, Ballal Rahul D. now owns 22,341 shares of Enliven Therapeutics Inc, valued at $1,279,068 using the latest closing price.
Ballal Rahul D., the Director of Enliven Therapeutics Inc, sale 13,600 shares at $21.01 during a trade that took place back on Apr 10 ’24, which means that Ballal Rahul D. is holding 22,341 shares at $285,744 based on the most recent closing price.
Stock Fundamentals for ELVN
The total capital return value is set at -0.34. Equity return is now at value -42.61, with -39.35 for asset returns.
Based on Enliven Therapeutics Inc (ELVN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -182.89. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 49.31.
Currently, EBITDA for the company is -83.23 million with net debt to EBITDA at 1.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.28.
Conclusion
To wrap up, the performance of Enliven Therapeutics Inc (ELVN) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
